Filing Flows › Monte Rosa Therapeutics (GLUE) › Q1 2025
Monte Rosa Therapeutics (GLUE) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Monte Rosa Therapeutics (GLUE) reported revenue of $84.9M for the first quarter 2025 (Q1 2025), up 80-fold from a year earlier and +40% from the quarter before. Operating margin was 51.9%, net earnings $46.9M (55.2% of revenue).
Monte Rosa Therapeutics, Q1 2025: revenue $84.9M (80× year over year), operating margin 51.9%, net earnings $46.9M, operating cash flow −$45.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $84.9M | +40% | 80× |
| Operating profit | $44.0M | +239% | — |
| Net earnings | $46.9M | +249% | — |
| Operating cash flow | −$45.5M | — | — |
What changed
Revenue was $84.9M in Q1 2025, up 7882% year over year and up 40% from the previous quarter.
Operating profit was $44.0M, a 51.9% margin (up 3336.3 points year over year). Total costs grew 14% against revenue growth of 7882%. The fastest-growing cost line was Research & development (+19%). Net earnings were $46.9M. The effective tax rate was 1.7%.
Operating cash flow was −$45.5M. Non-cash charges added back $2.6M of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items used $100.3M. Capital expenditures of $1.6M exceeded it, leaving free cash flow of −$47.1M.
Questions
What was Monte Rosa Therapeutics' revenue in the first quarter 2025?
Monte Rosa Therapeutics (GLUE) reported revenue of $84.9M for the first quarter 2025 (Q1 2025), up 80-fold from a year earlier and +40% from the quarter before.
Was Monte Rosa Therapeutics profitable in the first quarter 2025?
Operating profit was $44.0M (51.9% of revenue) and net earnings $46.9M.